Form 8-K - Current report:
SEC Accession No. 0001564590-21-027823
Filing Date
2021-05-14
Accepted
2021-05-14 08:32:13
Documents
12
Period of Report
2021-05-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K scyx-8k_20210513.htm   iXBRL 8-K 47852
  Complete submission text file 0001564590-21-027823.txt   178752

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA scyx-20210513.xsd EX-101.SCH 5776
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE scyx-20210513_lab.xml EX-101.LAB 19478
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE scyx-20210513_pre.xml EX-101.PRE 11630
5 EXTRACTED XBRL INSTANCE DOCUMENT scyx-8k_20210513_htm.xml XML 3544
Mailing Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548
Business Address 1 EVERTRUST PLAZA 13TH FLOOR JERSEY CITY NJ 07302-6548 201-884-5485
SCYNEXIS INC (Filer) CIK: 0001178253 (see all company filings)

EIN.: 562181648 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36365 | Film No.: 21922051
SIC: 2834 Pharmaceutical Preparations